Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Pharma scrambling on right-to-try

Momentum is intensifying rapidly for enactment of federal right-to-try legislation, forcing the pharmaceutical industry to scramble to determine whether and how to respond. On Tuesday, Vice President Pence invited right-to-try advocates to the White House and told them that he and President Trump strongly support their cause, according to

Read the full 491 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers